The past year has seen several combination therapies entering Phase I and II clinical trials, with some showing promising results while others facing challenges, especially in the treatment of solid tumors. The FDA Modernization Act 2.0 has encouraged the biopharmaceutical industry to shift away from animal models, allowing for more innovation in p
12-13 July 2023